The present invention provides a compound useful for treating adisorder associated with DGAT1 activity, wherein the compound has thefollowingstructure: A-Q-B-C-D wherein A is substituted or unsubstituted alkyl, alkoxy,cycloalkyl, aryl, heteroaryl or heterocyclyl； or optionally substituted amino；Q is adivalent or trivalent five membered heterocycle or heteroaryl； B is asubstituted orunsubstituted divalent heteroaryl group which is:(see formula I, see formula II, see formula III, see formula IV or see formulaV)；wherein X1-X4, X1' and X2' are as defined in the specification； C is(see formula VI)wherein R1, R'1, R2, R'2 are as defined in the specification, C may also be asubstituted or unsubstituted bicyclic aryl or heteroaryl group, and D ishydrogen,halogen, hydroxyl, cyano, alkanoylamino, carboxy, carbamoyl, -O-L2-E, -S-L2-E',-C(O)-O-L2-E, -L2-E", or ¨NR6-L2-E', wherein E, E', E", L2 and R6 are asdefined in thespecification, or a pharmaceutically acceptable salt thereof, or a prodrugthereof.
